[go: up one dir, main page]

AR065583A1 - Compuestos macrociclicos y composicion farmaceutica - Google Patents

Compuestos macrociclicos y composicion farmaceutica

Info

Publication number
AR065583A1
AR065583A1 ARP080100884A ARP080100884A AR065583A1 AR 065583 A1 AR065583 A1 AR 065583A1 AR P080100884 A ARP080100884 A AR P080100884A AR P080100884 A ARP080100884 A AR P080100884A AR 065583 A1 AR065583 A1 AR 065583A1
Authority
AR
Argentina
Prior art keywords
hydrogen atom
alkyl
alkenyl
halogen
compounds
Prior art date
Application number
ARP080100884A
Other languages
English (en)
Inventor
Hiroshi Koyano
Kihito Hada
Nobuo Shimma
Kenichi Kawasaki
Susumu Komiyama
Tadakatsu Hayase
Nao Ono
Takuo Tsukuda
Atsushi Suda
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR065583A1 publication Critical patent/AR065583A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuestos con actividad inhibidora de la enzima HSP90 y utiles como agentes anticancerosos o similares, y compuestos que son utiles como intermediarios sintéticos de los mismos y composicion farmacéutica. Reivindicacion 1: Un compuestorepresentado por la formula (1) o una sal del mismo aceptable para su uso farmacéutico, donde X representa CH o N; R1 representa un átomo de hidrogeno, halogeno, un grupo ciano, alquilo C1-6, haloalquilo C1-4, alquenilo C2-6, alquinilo C2-6, alcoxiC1-6, o alquiltio C1-6; R2 representa un átomo de hidrogeno, halogeno, un grupo alquilo C1-6, alquenilo C2-6, o alquinilo C2-6, o R2 y R3 juntos forman un anillo; R3 representa un átomo de hidrogeno, halogeno, un grupo ciano, alquilo C1-6, alqueniloC2-6, alquinilo C2-6, o alcoxi C1-6, o R2 y R3 juntos forman un anillo; R4 representa un átomo de hidrogeno, halogeno, un grupo alquilo C1-6, alquenilo C2-6, o alquinilo C2-6; R5, R6, y R7 representan cada uno independientemente un grupo alquilenoC1-6, alquenileno C2-6, alquinileno C2-6, cicloalquileno C3-10, cicloalquenileno C3-10, arileno C6-12, o anillo monociclico heterocíclico de entre 3 y 12 miembros, cada uno de los cuales puede tener un sustituyente; L1, L2, y L3 representan cada unoindependientemente una union simple, -CONR8-, -NR8CO-, -NR8-, -O-, -SO2NR8-, -NR8SO2-, -COO-, -NR8CONR8'-, -NR8COO-, o -OCONR8-; R8 y R8' representan cada uno independientemente un átomo de hidrogeno o un grupo alquilo C1-6 que puede tener unsustituyente.
ARP080100884A 2007-03-01 2008-02-29 Compuestos macrociclicos y composicion farmaceutica AR065583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007052072 2007-03-01

Publications (1)

Publication Number Publication Date
AR065583A1 true AR065583A1 (es) 2009-06-17

Family

ID=39721348

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100884A AR065583A1 (es) 2007-03-01 2008-02-29 Compuestos macrociclicos y composicion farmaceutica

Country Status (18)

Country Link
US (1) US8362236B2 (es)
EP (1) EP2119718B1 (es)
JP (1) JP5235859B2 (es)
KR (1) KR20090125155A (es)
CN (1) CN101675059A (es)
AR (1) AR065583A1 (es)
AT (1) ATE553107T1 (es)
AU (1) AU2008220009A1 (es)
BR (1) BRPI0808524A2 (es)
CA (1) CA2679126A1 (es)
CL (1) CL2008000629A1 (es)
IL (1) IL200009A0 (es)
MX (1) MX2009008756A (es)
PE (1) PE20090110A1 (es)
RU (1) RU2009136343A (es)
TW (1) TW200904435A (es)
WO (1) WO2008105526A1 (es)
ZA (1) ZA200905116B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061185A1 (es) * 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
CN101675059A (zh) 2007-03-01 2010-03-17 中外制药株式会社 大环状化合物
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CA2863892C (en) 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CA2867494C (en) * 2012-03-17 2020-03-24 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
EP2970334B1 (en) * 2013-03-15 2018-05-23 Biogen MA Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
PT3053578T (pt) 2013-09-30 2021-02-09 Taiho Pharmaceutical Co Ltd Terapêutica de combinação de cancro usando composto de azabiciclo
EP3623378B1 (en) * 2017-05-12 2025-07-02 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound
CN115124550B (zh) * 2020-10-26 2024-04-02 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用
WO2022089449A1 (zh) * 2020-10-26 2022-05-05 山东大学 一种特异性热休克蛋白90α亚型抑制剂制备及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5170780A (ja) 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinabenzoguanidoruino seiho
JPS60208968A (ja) 1984-03-07 1985-10-21 イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー 除草剤性フルオロエトキシピリミジン類及びトリアジン類
AU585761B2 (en) 1984-03-07 1989-06-22 E.I. Du Pont De Nemours And Company Herbicidal fluoroethoxy triazines
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
CA2263301A1 (en) 1996-11-01 1998-05-14 Warner-Lambert Company Isoquinolones
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU3378599A (en) 1998-04-03 1999-10-25 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
DE60110391T2 (de) 2000-02-25 2006-01-26 F. Hoffmann-La Roche Ag Adenosin-rezeptor modulatoren
WO2002002123A1 (en) 2000-06-29 2002-01-10 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
EP1337275A4 (en) 2000-11-02 2007-05-09 Sloan Kettering Inst Cancer METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS
KR100850727B1 (ko) 2000-11-02 2008-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90에 결합하기 위한 소분자 조성물
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US7291616B2 (en) 2001-10-31 2007-11-06 Cell Therapeutics, Inc. Aryl triazines as LPAAT-β inhibitors and uses thereof
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
DE60327994D1 (de) * 2002-02-08 2009-07-30 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
NZ546044A (en) 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
JP2005225787A (ja) * 2004-02-12 2005-08-25 Nippon Kayaku Co Ltd Ｈｓｐ９０阻害剤
GB0416168D0 (en) 2004-07-20 2004-08-18 Vernalis Cambridge Ltd Pyrmidothiophene compounds
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
WO2006123165A2 (en) 2005-05-19 2006-11-23 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
PT1951730E (pt) * 2005-11-16 2010-08-27 S Bio Pte Ltd Derivados de pirimidina ligados a heteroalquilo
AR061185A1 (es) * 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
CN101675059A (zh) 2007-03-01 2010-03-17 中外制药株式会社 大环状化合物
JP2009067729A (ja) 2007-09-14 2009-04-02 Kyowa Hakko Kirin Co Ltd Ｈｓｐ９０ファミリー蛋白質阻害剤
WO2009097578A1 (en) 2008-02-01 2009-08-06 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors

Also Published As

Publication number Publication date
US8362236B2 (en) 2013-01-29
JP5235859B2 (ja) 2013-07-10
ATE553107T1 (de) 2012-04-15
IL200009A0 (en) 2010-04-15
CL2008000629A1 (es) 2008-08-29
WO2008105526A1 (ja) 2008-09-04
EP2119718B1 (en) 2012-04-11
BRPI0808524A2 (pt) 2014-11-11
PE20090110A1 (es) 2009-04-04
CN101675059A (zh) 2010-03-17
ZA200905116B (en) 2010-07-28
US20100056510A1 (en) 2010-03-04
RU2009136343A (ru) 2011-04-10
EP2119718A1 (en) 2009-11-18
CA2679126A1 (en) 2008-09-04
TW200904435A (en) 2009-02-01
EP2119718A4 (en) 2010-12-15
KR20090125155A (ko) 2009-12-03
MX2009008756A (es) 2009-08-27
AU2008220009A1 (en) 2008-09-04
JPWO2008105526A1 (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
AR054799A1 (es) Derivados de oxindol
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
AR070558A1 (es) Derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino,proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de enfermedades dependientes de tirosinquinasas,tales como enfermedades proliferativas.
AR057131A1 (es) Derivados de purina como inmunomodulador
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR072576A1 (es) Metodo para la represion de malezas en un cesped
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR057688A1 (es) CARBOXAMIDAS HETEROCíCLICAS Y SU USO EN COMPOSICIONES FUNGICIDAS.
AR065280A1 (es) Agentes antiparasitarios
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR060050A1 (es) Compuestos moduladores del receptor de s1p y uso de los mismos
AR082153A1 (es) N-sulfonilbenzamidas utiles como inhibidor del canal de sodio
AR055635A1 (es) Uso de sulfonanilidas como herbicidas
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
UY33458A (es) Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos
ECSP055974A (es) Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR078270A1 (es) Inhibidores de jak (quinasas janus)
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure